EE229 Cost-Effectiveness Analysis of Eremumab (Aimovig®) for the Preventive Treatment of Migraine in Spain
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.477
https://www.valueinhealthjournal.com/article/S1098-3015(22)02681-X/fulltext
Title :
EE229 Cost-Effectiveness Analysis of Eremumab (Aimovig®) for the Preventive Treatment of Migraine in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02681-X&doi=10.1016/j.jval.2022.09.477
First page :
Section Title :
Open access? :
No
Section Order :
12285